...
....
Pharmaceutical
Biotechnology

> See specialized channels
Medical Devices & Diagnostics
> See specialized channels
Industrial
Biotechnology
> See specialized channels


  Join us

  Follow us on Twitter   Join our LinkedIn Group   Our Blog

Biotech News App
Provides access to the latest biotech press releases ...more

Android_Logo App Store RIM_Logo_small

Media Partnership:
Want to have your RSS feed integrated on our website? Contact us
RSS Feeds RSS Feeds
JoomlaWatch Stats 1.2.9 by Matej Koval
For Editors
Sign up for press releases
For Companies
Sign up for our newsletter
Back to PRESS RELEASES - 

ElexoPharm GmbH Receives EuroTransBio (ETB) Grant for Tumor Vessel Targeting Program (‘Small Mol Act’)

| Print |
Wednesday, 17 October 2012 13:15 (UTC + 2)
ETB_Logo ElexoPharm_Logo

Saarbrücken, Germany, October 17, 2012 / B3C newswire / - Recently, a EuroTransBio grant of €1.5 million has been awarded to a transnational consortium including ElexoPharm GmbH by the European Collaborative ETB program. The project is a collaboration of ElexoPharm GmbH with SomantiX BV (Bilthoven, The Netherlands), VU University Medical Center (Amsterdam, The Netherlands), Saarland University (Saarbrücken, Germany) and PharmBioTec GmbH (Saarbrücken, Germany). This subsidy is awarded for a period of three years and will allow the development of low molecular weight inhibitors of angiogenesis in colorectal cancer. At ElexoPharm, lead finding and lead optimization based on molecular modelling, design and synthesis of biological active compounds, will be performed.

"ElexoPharm is very proud to have received this prestigious transnational grant to develop medicines to treat this disease of high medical need. It is a further recognition of the excellent drug discovery capabilities of our growing company", states Axel Koch, Managing Director of ElexoPharm.

 
About Elexopharm
ElexoPharm GmbH is a German biotech company located in Saarbrücken, founded as a spin-off of the Department of Pharmaceutical and Medicinal Chemistry of Saarland University headed by Professor Rolf Hartmann. ElexoPharm is focused on the preclinical discovery and optimization of novel innovative drugs for human diseases, which are currently not or insufficiently treatable with existing drugs. One of the largest success of ElexoPharm was the execution of an exclusive license and collaboration agreement with Merck & Co. Inc. for one of its own research projects (development of aldosterone synthase inhibitors for the treatment of cardiovascular diseases) in 2010.

 
Contact
Axel Koch, MBA
Managing Director
ElexoPharm GmbH
Im Stadtwald, A1.1
66123 Saarbrücken
Germany
Phone: +49 (0) 681 - 302 68320
Fax: +49 (0) 681 - 910 2894
Email: This e-mail address is being protected from spambots. You need JavaScript enabled to view it
www.elexopharm.de